ArticleCancer immunology, immunotherapy : CII2026
Seasonal variation in immune-related adverse events in advanced cancer patients.
Article in Cancer immunology, immunotherapy : CII, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundImmune checkpoint inhibitors (ICIs) improve outcomes across advanced cancers but can cause immune-related adverse events (irAEs). Seasonal environmental factors influence immune regulation and autoimmunity, yet its relationship with irAE development in non-melanoma cancers remains poorly defined.
methodsWe retrospectively analysed patients with advanced non-melanoma solid tumours treated with anti-PD-1/PD-L1 and/or anti-CTLA-4 monotherapy at two Australian tertiary centers between 2014-2024. Seasonal variation in irAE incidence, organ distribution, severity, and timing were evaluated using descriptive analyses, Kaplan-Meier estimates and Cox proportional hazards models.
resultsAmong 709 patients across 27 cancer types (median follow-up 12.7 months), 514 irAEs occurred, including 32% grade ≥ 3 events and 14% treatment discontinuation rate due to toxicity. Winter ICI initiation led to the highest irAE rate (0.89 events per treatment) versus summer (0.62), largely driven by seasonal variation in low-grade cutaneous and thyroid events. Summer ICI initiation showed the highest proportion of grade ≥ 3 irAEs, whereas winter had the lowest. Seasonal effects also differed by regimen intensity, with disproportionately more irAEs among patients commencing doublet ICIs in winter. Season of ICI initiation was not significantly associated with overall irAE risk (p = 0.174) or time to onset (p = 0.11). However, time to first irAE differed by season of toxicity onset (p = 0.019), with earlier irAEs occurring in spring and summer.
conclusionsAlthough there was no significant association between season of ICI initiation and overall irAE risk, we observed seasonal variations in the phenotype, severity, and timing of irAEs. These exploratory findings may inform future investigation into seasonal influences on immune toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.